ProAir Shortage: What Providers and Prescribers Need to Know in 2026

The albuterol shortage that began in October 2022 has been one of the most consequential drug supply disruptions in recent memory — affecting one of the most widely prescribed rescue medications in the United States. While the overall situation has improved in 2026, providers continue to encounter patients who cannot fill their prescriptions or who need clinical guidance on appropriate alternatives. This guide summarizes the current shortage landscape, therapeutic alternatives, and practical guidance for clinical practice.

Current Shortage Status (2026)

As of 2026, the shortage landscape is as follows:

Albuterol HFA metered-dose inhalers: Generally available at most retail and hospital pharmacies. The ProAir HFA brand was discontinued by Teva in October 2022; authorized generics remain in supply. Ventolin HFA (GSK) and Proventil HFA (Merck) remain available. Local stock-outs during peak respiratory season continue to occur.

Albuterol sulfate inhalation solution (nebulizer): Still on the FDA shortage list since October 2022, but improving. Ritedose Pharmaceuticals was approved in November 2025 and Amneal Pharmaceuticals in March 2026 as new generic manufacturers. Supply disruptions may persist through mid-2026 as new production ramps up.

Dry powder inhalers (ProAir RespiClick): Not affected by the shortage. Available as both brand and authorized generic.

Therapeutic Alternatives: Clinical Considerations

Other Albuterol HFA Inhalers

Ventolin HFA (GSK) and Proventil HFA (Merck) are therapeutically equivalent to generic albuterol HFA and can be substituted with a new prescription. Note that although the active ingredient and dosage are identical (90 mcg albuterol base/actuation), these products are not interchangeable by the pharmacist under existing drug substitution regulations without a new prescription. Research has shown differences in spray characteristics between brands (ProAir HFA delivered a warmer, softer spray with a higher fine particle dose than Ventolin HFA in some studies), but these differences are not considered clinically significant. When writing alternative prescriptions, specify "albuterol sulfate HFA inhaler — dispense any available brand" to give pharmacists flexibility.

ProAir RespiClick (Dry Powder Inhaler)

ProAir RespiClick is breath-activated and does not require hand-breath coordination, making it potentially better for certain patient populations including older adults and young children (ages 4+). Key clinical considerations:

Contains lactose — contraindicated in patients with severe milk protein allergy

Requires adequate inspiratory flow rate — may not be appropriate for severe acute exacerbations

Do not shake or prime — patient education is essential when switching from MDI

Cannot be used with a spacer

Levalbuterol (Xopenex HFA)

Levalbuterol HFA (Xopenex HFA) is FDA-approved for treatment and prevention of bronchospasm in patients 4 years and older. It is the purified R-enantiomer of albuterol and delivers 45 mcg per actuation (vs. 90 mcg for albuterol). Clinical evidence shows similar efficacy and safety profiles at equipotent doses. Historically cited advantages of levalbuterol in reducing cardiovascular side effects have not been consistently demonstrated in head-to-head clinical trials. Levalbuterol is typically significantly more expensive than generic albuterol and may not be on formulary for some Medicare and Medicaid plans. It may be useful as an alternative for patients who report significant tremor, tachycardia, or hypokalemia with standard albuterol doses, or when albuterol supply is unavailable at local pharmacies.

Airsupra (Albuterol/Budesonide)

Airsupra is an FDA-approved combination rescue inhaler containing albuterol (180 mcg/actuation) and budesonide (160 mcg/actuation). It is indicated for adults with asthma for as-needed relief. The anti-inflammatory component may help prevent post-exacerbation inflammation. Consider this option for patients with moderate-to-severe asthma who are frequent rescue inhaler users and have commercial insurance (the SUPRA Savings Card can reduce cost to $0). Not a first-line substitute for cost reasons, and not approved for COPD or pediatric use.

Practical Prescribing Recommendations

Write flexible prescriptions: When prescribing albuterol, consider adding a note that any brand of albuterol HFA inhaler is acceptable, giving pharmacists flexibility during stock-outs.

Pre-authorize alternatives: Document in the patient's chart that Ventolin HFA or Proventil HFA are acceptable alternatives. This allows staff to send a prescription quickly without needing another provider visit during a shortage.

Counsel patients on proactive refilling: Remind patients to refill their rescue inhaler before the dose counter reaches 50 (out of 200). Early September — before respiratory virus season — is a good target for annual refill planning discussions.

Assess controller therapy adequacy: Patients using rescue inhalers more than twice per week should be evaluated for initiation or step-up of inhaled corticosteroid therapy. Reducing rescue inhaler dependence is protective when supply is limited.

Use medfinder for pharmacy availability: Direct patients to use medfinder, which calls pharmacies on their behalf to find which ones have their specific albuterol product in stock. This reduces the burden of pharmacy hunting for both patients and your staff.

Counseling Your Patients on Shortage Preparedness

Key messages for patients during respiratory shortage seasons:

Never skip or ration doses during an acute exacerbation — use as directed, then find a refill

Know the alternative brand names for albuterol (Ventolin HFA, Proventil HFA, generic albuterol HFA)

Use medfinder to locate nearby pharmacies with stock rather than calling each one individually

Seek medical care promptly for any worsening symptoms, especially if their usual rescue dose is not providing relief within 20 minutes

For more clinical guidance on navigating the shortage with your patients, visit medfinder for providers or read our provider guide to helping patients find ProAir in stock.